By Gina Shaw
SAN DIEGO—The high price tags and front-loaded cost burden of novel gene therapies are leading payors to experiment with innovative approaches to manage their financial risk, according to experts at a gene therapy–focused half-day Specialty Connect session held at the 2019 annual AMCP Managed Care & Specialty Pharmacy meeting.
“Nothing has disrupted how we code and pay and reimburse as much as gene therapy has,” said Clifford Goodman, PhD, the senior vice